Indakaterol

Indakaterol
Klinički podaci
Prodajno ime	Arcapta, Hirobriz, Onbrez, Onbrize
Drugs.com	Monografija
Način primene	Respiratorno (inhalacija)
Farmakokinetički podaci
Poluvreme eliminacije	45,5 - 126 h
Izlučivanje	Fekalno (54%)
Identifikatori
CAS broj	312753-06-3
ATC kod	R03AC18 (WHO)
PubChem	CID 6433117
DrugBank	DB05039
ChemSpider	5293751
ChEBI	CHEBI:68575
ChEMBL	CHEMBL1095777
Hemijski podaci
Formula	C24H28N2O3
Molarna masa	392,491
	SMILES CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1; ;
	InChI InChI=1S/C24H28N2O3/c1-3-14-9-16-11-18(12-17(16)10-15(14)4-2)25-13-22(28)19-5-7-21(27)24-20(19)6-8-23(29)26-24/h5-10,18,22,25,27-28H,3-4,11-13H2,1-2H3,(H,26,29)/t22-/m0/s1 ; Key:QZZUEBNBZAPZLX-QFIPXVFZSA-N ;
Fizički podaci
Tačka topljenja	195—202 °C (383—396 °F)

Indakaterol je organsko jedinjenje, koje sadrži 24 atoma ugljenika i ima molekulsku masu od 392,491 Da.^[1]^[2]^[3]^[4]^[5]^[6]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	4
Broj donora vodonika	4
Broj rotacionih veza	6
Particioni koeficijent^[7] (ALogP)	3,9
Rastvorljivost^[8] (logS, log(mol/L))	-6,5
Polarna površina^[9] (PSA, Å²)	81,6

Reference

^ Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M: Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. Naline, E.; Trifilieff, A.; Fairhurst, R. A.; Advenier, C.; Molimard, M. (март 2007). „Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi”. The European Respiratory Journal. 29 (3): 575—81. PMID 17135231. doi:10.1183/09031936.00032806. . Epub 2006 Nov 29.
^ Australian Public Assessment Report:http://www.tga.gov.au/pdf/auspar/auspar-onbrez.pdf Архивирано на веб-сајту Wayback Machine (12. фебруар 2014)
^ Kagan M, Dain J, Peng L, Reynolds C: Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos. Kagan, Mark; Dain, Jeremy; Peng, Lana; Reynolds, Christine (септембар 2012). „Metabolism and Pharmacokinetics of Indacaterol in Humans”. Drug Metabolism and Disposition. 40 (9): 1712—22. PMID 22648561. doi:10.1124/dmd.112.046151. .. Epub 2012 May 30.
^ Reid DJ, Pham NT: Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15.Reid, D. J.; Pham, N. T. (април 2013). „Emerging Therapeutic Options for the Management of COPD”. Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine. 7: 7—15. PMC 3629926 . PMID 23641160. doi:10.4137/CCRPM.S8140. . Print 2013.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Indacaterol

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Naline E, Trifilieff A, Fairhurst RA, Advenier C, Molimard M: Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. Naline, E.; Trifilieff, A.; Fairhurst, R. A.; Advenier, C.; Molimard, M. (март 2007). „Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi”. The European Respiratory Journal. 29 (3): 575—81. PMID 17135231. doi:10.1183/09031936.00032806. . Epub 2006 Nov 29.

[2] Australian Public Assessment Report:http://www.tga.gov.au/pdf/auspar/auspar-onbrez.pdf Архивирано на веб-сајту Wayback Machine (12. фебруар 2014)

[3] Kagan M, Dain J, Peng L, Reynolds C: Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos. Kagan, Mark; Dain, Jeremy; Peng, Lana; Reynolds, Christine (септембар 2012). „Metabolism and Pharmacokinetics of Indacaterol in Humans”. Drug Metabolism and Disposition. 40 (9): 1712—22. PMID 22648561. doi:10.1124/dmd.112.046151. .. Epub 2012 May 30.

[4] Reid DJ, Pham NT: Emerging Therapeutic Options for the Management of COPD. Clin Med Insights Circ Respir Pulm Med. 2013 Apr 9;7:7-15.Reid, D. J.; Pham, N. T. (април 2013). „Emerging Therapeutic Options for the Management of COPD”. Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine. 7: 7—15. PMC 3629926 . PMID 23641160. doi:10.4137/CCRPM.S8140. . Print 2013.

[5] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[6] Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[7] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[8] Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[9] Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]